These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31276604)

  • 1. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.
    Sawada Y; Kikugawa T; Iio H; Sakakibara I; Yoshida S; Ikedo A; Yanagihara Y; Saeki N; Győrffy B; Kishida T; Okubo Y; Nakamura Y; Miyagi Y; Saika T; Imai Y
    Int J Cancer; 2020 Mar; 146(5):1369-1382. PubMed ID: 31276604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells.
    Zhou C; Dai X; Chen Y; Shen Y; Lei S; Xiao T; Bartfai T; Ding J; Wang MW
    Oncotarget; 2016 Mar; 7(11):12823-39. PubMed ID: 26871479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
    Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
    Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.
    Dey P; Jonsson P; Hartman J; Williams C; Ström A; Gustafsson JÅ
    Mol Endocrinol; 2012 Dec; 26(12):1991-2003. PubMed ID: 23028063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.
    Chen WY; Liu SY; Chang YS; Yin JJ; Yeh HL; Mouhieddine TH; Hadadeh O; Abou-Kheir W; Liu YN
    Oncotarget; 2015 Jan; 6(1):441-57. PubMed ID: 25436980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPRC5A promotes gallbladder cancer metastasis by upregulating TNS4 via the JAK2-STAT3 pathway.
    Yang J; Li X; Chen S; Li G; Pu P; Yang Y; Wu W; Geng Y; Liu Y
    Cancer Lett; 2024 Aug; 598():217067. PubMed ID: 38942137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3β in Pancreatic Cancer.
    Liu B; Yang H; Pilarsky C; Weber GF
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29949874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
    Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
    Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of S100A4 for bone metastasis in prostate cancer cells.
    Kim B; Jung S; Kim H; Kwon JO; Song MK; Kim MK; Kim HJ; Kim HH
    BMC Cancer; 2021 Feb; 21(1):137. PubMed ID: 33549040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation of GPRC5A expression in colorectal cancer promotes tumor progression through VNN-1 induced oxidative stress.
    Zhang L; Li L; Gao G; Wei G; Zheng Y; Wang C; Gao N; Zhao Y; Deng J; Chen H; Sun J; Li D; Zhang X; Liu M
    Int J Cancer; 2017 Jun; 140(12):2734-2747. PubMed ID: 28316092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKCε Is an Essential Mediator of Prostate Cancer Bone Metastasis.
    Gutierrez-Uzquiza A; Lopez-Haber C; Jernigan DL; Fatatis A; Kazanietz MG
    Mol Cancer Res; 2015 Sep; 13(9):1336-46. PubMed ID: 26023164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
    Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
    Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
    Fort RS; Mathó C; Geraldo MV; Ottati MC; Yamashita AS; Saito KC; Leite KRM; Méndez M; Maedo N; Méndez L; Garat B; Kimura ET; Sotelo-Silveira JR; Duhagon MA
    BMC Cancer; 2018 Feb; 18(1):127. PubMed ID: 29394925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPRC5A overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer.
    Liu H; Zhang Y; Hao X; Kong F; Li X; Yu J; Jia Y
    Tumour Biol; 2016 Jan; 37(1):503-10. PubMed ID: 26227221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.
    Feng S; Agoulnik IU; Truong A; Li Z; Creighton CJ; Kaftanovskaya EM; Pereira R; Han HD; Lopez-Berestein G; Klonisch T; Ittmann MM; Sood AK; Agoulnik AI
    Endocr Relat Cancer; 2010 Dec; 17(4):1021-33. PubMed ID: 20861284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
    Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
    Song H; Sun B; Liao Y; Xu D; Guo W; Wang T; Jing B; Hu M; Li K; Yao F; Deng J
    Int J Cancer; 2019 Feb; 144(4):777-787. PubMed ID: 29992578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
    Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.
    Zoni E; Astrologo L; Ng CKY; Piscuoglio S; Melsen J; Grosjean J; Klima I; Chen L; Snaar-Jagalska EB; Flanagan K; van der Pluijm G; Kloen P; Cecchini MG; Kruithof-de Julio M; Thalmann GN
    Mol Cancer Res; 2019 May; 17(5):1049-1062. PubMed ID: 30745464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.